ABSTRACT
Surgically accessible lesions of chronic thromboembolic pulmonary hypertension (CTEPH) are classified as proximal or distal based on the distribution of thrombus burden in the pulmonary vasculature post operatively. Surgically accessible distal CTEPH lesions typically has a higher risk profile and worse clinical outcomes in less experienced centers, but the underlying molecular differences between proximal and distal CTEPH lesions remain unknown. Oxylipins, a diverse group of bioactive lipid mediators, have previously been implicated in a range of disorders including pulmonary hypertension. Therefore, we sought to characterize oxylipin profiles among patients with proximal and distal operable CTEPH lesions, as well as those with idiopathic pulmonary arterial hypertension (IPAH). We studied 271 patients with proximal operable CTEPH (n=123), distal operable CTEPH (n=74), or IPAH (n=74). Liquid chromatography-mass spectrometry was used to analyze oxylipin profiles in each patient. We found that patients with distal operable CTEPH had elevated levels of proinflammatory oxylipins while those with proximal CTEPH had an increase in procoagulant oxylipins. Notably, the proinflammatory oxylipins elevated in distal operable CTEPH were similarly elevated in IPAH. These findings suggest that distal operable and proximal CTEPH represent heterogenous disease processes. Furthermore, oxylipin profiles may be useful for potential risk stratification and therapeutic targeting in CTEPH.
Competing Interest Statement
None of the authors have any potential conflicts of interest relative to the study. NHK has served as consultant for Bayer, Janssen, Merck, United Therapeutics and has received lecture fees for Bayer, Janssen. NHK has received research support from Acceleron, Eiger, Gossamer Bio, Lung Biotechnology, SoniVie. A.M.B. served as a consultant to Biogen.
Funding Statement
This work was supported in part by National Institutes of Health (NIH) grants S10OD020025, R01ES027595, K01DK116917, R01HL131532, R01HL151828, U54AG065141, R24HL105333 and a pulmonary hypertension PHAB award from Bayer.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UCSD IRB approved the study protocols and all patients signed an informed consent at their respective institutions.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Requests for de-identified data may be directed to the corresponding authors (NHK, SC) and will be reviewed by the Office of Research Administration at UCSD prior to issuance of data sharing agreements. Data limitations are designed to ensure patient and participant confidentiality.
Non-standard Abbreviations and Acronyms
- BMI
- Body mass index
- CTEPH
- Chronic thromboembolic pulmonary hypertension
- IPAH
- Idiopathic pulmonary arterial hypertension
- LC-MS
- Liquid chromatography - mass spectrometry
- mRAP
- Mean right atrial pressure
- PAH
- Pulmonary arterial hypertension
- PEA
- Pulmonary endarterectomy
- PVR
- Pulmonary vascular resistance
- RHC
- Right heart catheterization
